Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL

Tabbara, Nadeem; Gaut, Daria; Oliai, Caspian; Lewis, Tara; Vos, Sven de

doi:10.1016/j.lrr.2021.100260

Cited by 9 publications

(8 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tabbara and colleagues described a case of a patient receiving axicabtagene ciloleucel 4 months after the administration of the last cycle of tafasitamab and lenalidomide for refractory DLBCL. 70 This patient obtained a complete remission after axicabtagene ciloleucel treatment, which was sustained up to 24 months. Regarding loncastuximab tesirine, the series by Thapa and colleagues reported the outcome of 14 patients receiving commercial or investigational CD19-CAR T cells for DLBCL R/R after loncastuximab tesirine treatment in the context of two phase I and II clinical trials.…”

Section: Reported Clinical Experience Of Cd19targeting Therapies Sequ...mentioning

confidence: 73%

“…Very limited experience with CAR T cell therapy has been reported after treatment with tafasitamab or loncastuximab. Tabbara and colleagues described a case of a patient receiving axicabtagene ciloleucel 4 months after the administration of the last cycle of tafasitamab and lenalidomide for refractory DLBCL 70 . This patient obtained a complete remission after axicabtagene ciloleucel treatment, which was sustained up to 24 months.…”

Section: Aspects Influencing Cd19‐targeting Treatment Choice and Sequ...mentioning

confidence: 99%

See 1 more Smart Citation

How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?

de Ramon Ortiz,

Wang,

Stathis

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

About one third of patients with diffuse large B‐cell lymphoma (DLBCL) have a relapsing/refractory (R/R) disease after first line chemo‐immunotherapy, with particularly poor outcomes observed in patients with primary refractory disease and early relapse. CD19 specific chimeric antigen receptor (CAR) T cell therapy is a game changer that results in durable and complete response rates in almost half of the patients with R/R DLBCL. Other emerging CD19‐targeting therapies include monoclonal antibodies, bispecific antibodies and targeting antibody‐drug conjugates, which also show encouraging results. However, the timing and sequencing of different anti‐CD19‐targeting agents and how they might interfere with subsequent CAR T cell treatment is still unclear. In this review, we summarize the results of the pivotal clinical trials as well as evidence from real‐world series of the use of different CD19‐targeting approved agents. We discuss the effect of various therapies on CD19 expression and its implications for treatment sequencing.

show abstract

Section: Reported Clinical Experience Of Cd19targeting Therapies Sequ...mentioning

confidence: 73%

Section: Aspects Influencing Cd19‐targeting Treatment Choice and Sequ...mentioning

confidence: 99%

How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?

de Ramon Ortiz,

Wang,

Stathis

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Interestingly, remission of DLBCL after CART19 was reported in one patient who previously failed to Tafasitamab. CD19-targeted therapies could be effective despite being administered sequentially ( 122 ).…”

Section: Treatment Options After Cart19 Failurementioning

confidence: 99%

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure

et al. 2022

View full text Add to dashboard Cite

Immunotherapy with T cells genetically modified with chimeric antigen receptors (CARs) has shown significant clinical efficacy in patients with relapsed/refractory B-cell lymphoma. Nevertheless, more than 50% of treated patients do not benefit from such therapy due to either absence of response or further relapse. Elucidation of clinical and biological features that would predict clinical response to CART19 therapy is of paramount importance and eventually may allow for selection of those patients with greater chances of response. In the last 5 years, significant clinical experience has been obtained in the treatment of diffuse large B-cell lymphoma (DLBCL) patients with CAR19 T cells, and major advances have been made on the understanding of CART19 efficacy mechanisms. In this review, we discuss clinical and tumor features associated with response to CART19 in DLBCL patients as well as the impact of biological features of the infusion CART19 product on the clinical response. Prognosis of DLBCL patients that fail CART19 is poor and therapeutic approaches with new drugs are also discussed.

show abstract

“…Unlike tafasitamab, loncastuximab, and the currently approved CAR T cell products, which target CD19, polatuzumab targets CD79b and, therefore, treatment with BR-pola might be preferred in patients who progress on prior CD19-directed therapies. Notably, the limited data show that progression on one type of CD19-directed therapy does not preclude responses to other CD19-directed therapies as evident by the responses seen in the small number of patients who received CAR T cells before loncastuximab on the LOTIS-2 trial (although biopsy-proven CD19 expression was required in the LOTIS-2 trial) as well as responses to CAR T-cell therapies in patients who received prior loncastuximab or lenalidomide plus tafasitamab [27,43,44].…”

Section: Clinical Considerationsmentioning

confidence: 99%

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies

Sawalha

2021

JPM

View full text Add to dashboard Cite

Approximately 40% of patients with diffuse large B cell lymphoma (DLBCL) do not respond or develop relapsed disease after first-line chemoimmunotherapy. A minority of these patients can be cured with autologous hematopoietic stem cell transplantation (AHCT). Although chimeric antigen receptor (CAR) T cells have transformed the treatment paradigm of relapsed/refractory DLBCL, only 30–40% of patients achieve durable remissions. In addition, many patients with relapsed/refractory DLBCL are ineligible to receive treatment with CAR T cells due to comorbidities or logistical limitations. Since 2019, the following four non-CAR T-cell treatments have been approved in relapsed/refractory DLBCL: polatuzumab in combination with bendamustine and rituximab, selinexor, tafasitamab plus lenalidomide, and loncastuximab. In this article, I review the data behind these four approvals and discuss important considerations on their use in clinical practice. I also review emerging therapies that have shown promising early results in relapsed/refractory DLBCL including the bispecific antibodies, antibody–drug conjugates, Bruton tyrosine kinase inhibitors, BCL2 inhibitors, immune checkpoint inhibitors, and epigenetic modifiers.

show abstract

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL

Cited by 9 publications

References 10 publications

How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?

How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies

Contact Info

Product

Resources

About